Core Insights - Ginkgo Bioworks aims to expand its Boston-based autonomous lab and create an AI-driven biological research platform, deploying multiple RAC systems to lower the cost and accessibility of scientific experiments [1] Group 1: AI and Scientific Revolution - The combination of AI and automated laboratories is expected to fundamentally change the paradigm of scientific research and the biopharmaceutical industry, leading to true disruption [1] - Previous technological revolutions did not fundamentally alter the biotechnology and biopharmaceutical sectors, but AI's integration is seen as a game-changer [1] Group 2: Ginkgo Bioworks' Strategic Focus - Ginkgo's mission is to make biology more engineering-friendly, focusing on "programming cells" [1] - The company's strategic emphasis has shifted from "AI-designed biology" to making laboratory testing and validation cheaper and faster, viewing the latter as a solvable engineering problem [1] Group 3: AI-Driven Automated Laboratories - Collaboration with OpenAI has demonstrated that AI models can autonomously design and conduct scientific experiments, achieving a 40% efficiency increase in optimizing "cell-free protein synthesis" through six iterations [2] - The cost structure of scientific research is revolutionized, with over 95% of costs currently attributed to labor, lab space, and equipment, while automated labs can flip this structure, making reagents the primary cost and achieving over tenfold data output efficiency [2] - AI scientists can work 24/7 and share raw experimental data in real-time, enhancing collaboration and learning compared to the traditional publication model [2] - Ginkgo addresses the challenge of automating diverse and non-standardized laboratory tasks by integrating third-party equipment and using AI to convert natural language instructions into executable code for robots [2] Group 4: Biotechnology Application Prospects - Currently, 85% of the biotechnology market is focused on therapeutics, indicating a narrow application ecosystem [3] - Promising new directions include consumer-grade biotechnology, such as GLP-1 drugs in the "health enhancement" sector, which has a market potential that far exceeds disease treatment [3] - Continuous health monitoring at the molecular level through frequent blood tests is seen as a way to achieve personalized health interventions [3] - The share of biotechnology transactions from Chinese companies has recently increased, attributed to lower costs and faster clinical trial processes in China [3] - The U.S. needs to leverage AI and automated laboratories to enhance research efficiency and maintain technological competitiveness [3]

Group 1: Strategic Transformation - The core direction of the company's strategic transformation this year is shifting from the traditional FTE subcontracting model to a full-package service model, providing a one-stop delivery service from target discovery to PCC and IND application in preclinical stages [2] - The full-package service model aims to enhance delivery efficiency and service quality for clients, accelerating their R&D processes while creating a differentiated competitive barrier for the company [2] - The company is investing in industry funds to focus on early-stage project investments, participating deeply in project selection, technology validation, and execution, which supports both early innovation projects and the company's future full-package business [2][3] Group 2: Core Technology Layout - The company is advancing new technology layouts in four cutting-edge areas: AI technology, automated laboratories, organoids, and ultra-limited manufacturing [4] - Strategic investment in AI technology through collaboration with Beijing Zheyuan Technology aims to integrate resources and enhance drug discovery efficiency and success rates [4] - A deep strategic partnership with Suzhou Meijia Technology focuses on building an automated laboratory to upgrade R&D capabilities from concept validation to PCC [4] - Collaboration with Tsinghua Chang Gung Hospital aims to establish an organoid innovation center, preparing for reduced animal testing trends and providing efficient preclinical evaluation solutions [4] Group 3: Talent Structure Optimization - The company is continuously optimizing its talent structure and organizational capabilities to enhance commercial thinking and cross-departmental collaboration [5] - Expansion of the BD team and restructuring of the overseas market team are aimed at improving global client development, project acquisition, and service delivery capabilities [5][6] - Implementation of a restricted stock incentive plan in 2025 covers core management and technical personnel, binding them to the company's long-term development and enhancing team motivation and creativity [6] - Strengthening employee care systems through various initiatives aims to enhance corporate cohesion and employee sense of belonging, supporting the company's strategic implementation and high-quality development [6]

Core Viewpoint - Dongguan Changlian New Materials Technology Co., Ltd. held an online investor reception day on September 19, 2025, to enhance communication with investors and provide insights into the company's operations and strategies [1] Group 1: R&D Achievements - As of June 30, 2025, the company has obtained 41 invention patents and 7 utility model patents, indicating a strong focus on innovation and product development [2] Group 2: Cost Control Measures - The company has established a "three-in-one" cost control system, focusing on procurement, production, and R&D to enhance efficiency and reduce costs [2] - In procurement, the company leverages large-scale purchasing and long-term partnerships with key suppliers to secure cost advantages [2] - The production side utilizes self-developed automated cleaning production technology to improve efficiency and reduce labor and energy costs [2] - In R&D, the company develops core raw materials and optimizes product formulas and processes to minimize material waste and manufacturing expenses [2] Group 3: Environmental Strategy - The company integrates environmental protection and safety production into its sustainable development strategy, aiming to reduce pollutant emissions through improved production processes [2] - Regular safety education and training are conducted to adhere to safety guidelines [2] Group 4: Automation Laboratory Empowerment - The automated printing laboratory simulates customer production scenarios to collect data and analyze the downstream textile printing process, providing application solution recommendations to clients [2] Group 5: Response to Raw Material Price Fluctuations - In response to international oil price fluctuations, the company plans to strengthen supply chain management and establish stable long-term partnerships with suppliers to lower procurement costs [2] - The company aims to enhance product quality and service capabilities to improve bargaining power and maintain stable operations [2]